Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact.
The start of the Phase I trial for IDE034 triggers a milestone payment to Biocytogen, from which Ideaya acquired the program in 2024.
With an increasing number of complex circuits being integrated into SoCs, their testing requirements have become equally complex. While there are well established test strategies for digital circuits, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results